"FDA DEFENSE" AMENDMENT INCLUDED IN PRODUCT LIABILITY LEGISLATION PASSED BY HOUSE MARCH 10; HR 956 INCLUDES NON-ECONOMIC DAMAGES CEILING OF $250,000
"FDA defense" language is a provision of product liability legislation passed by the House on March 9. Prior to the vote, amendment co-sponsor Rep. Oxley (R-Ohio) reported that the amendment was supported by at least 245 members. The full bill (HR 956) cleared the House March 10 by a 265-161 vote.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth